Nintedanib in patients with progressive fibrosing ILDs in subgroups by comorbidity burden

被引：0

作者：

Bendstrup, E. ^{[1
]}

Moua, T. ^{[2
]}

Okamoto, M. ^{[3
]}

Tomassetti, S. ^{[4
]}

Valenzuela, C. ^{[5
]}

Wuyts, A. ^{[6
]}

Miede, C. ^{[7
]}

Lievens, D. ^{[8
]}

Bonella, F. ^{[9
]}

机构：

[1] Aarhus Univ Hosp, Dept Resp Dis & Allergy, Ctr Rare Lung Dis, Aarhus, Denmark

[2] Mayo Clin Rochester, Div Pulm & Crit Care Med, Rochester, MN USA

[3] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan

[4] Careggi Univ Hosp, Dept Expt & Clin Med, Florence, Italy

[5] Univ Autonoma Madrid, Hosp Univ Princesa, Madrid, Spain

[6] Univ Hosp Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium

[7] Mainanalytics GmbH, Sulzbach, Taunus, Germany

[8] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[9] Univ Duisburg Essen, Pneumol Dept, Ctr Interstitial & Rare Lung Dis, Ruhrlandklin, Essen, Germany

来源：

关键词：

D O I：

10.1183/13993003.congress-2022.615

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：2